Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 627 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $26.33, for a total transaction of $16,508.91. Following the sale, the general counsel directly owned 20,598 shares of the company’s stock, valued at approximately $542,345.34. This trade represents a 2.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, August 18th, Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $91,637.83.

Stoke Therapeutics Trading Down 1.5%

NASDAQ:STOK traded down $0.39 during mid-day trading on Friday, hitting $25.62. The company had a trading volume of 581,420 shares, compared to its average volume of 783,759. The business has a fifty day simple moving average of $29.99 and a 200-day simple moving average of $31.21. Stoke Therapeutics, Inc. has a 1 year low of $20.32 and a 1 year high of $40.22. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -7.67 and a beta of 1.26.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The company had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. Tidal Investments LLC raised its stake in shares of Stoke Therapeutics by 16.1% in the 2nd quarter. Tidal Investments LLC now owns 9,917 shares of the company’s stock valued at $324,000 after purchasing an additional 1,377 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Stoke Therapeutics in the second quarter worth about $959,000. Corient Private Wealth LP bought a new stake in Stoke Therapeutics in the second quarter valued at about $1,009,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Stoke Therapeutics in the second quarter valued at about $443,000. Finally, Seven Fleet Capital Management LP acquired a new stake in Stoke Therapeutics during the second quarter valued at approximately $255,000.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Guggenheim reissued a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Wedbush boosted their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Canaccord Genuity Group decreased their target price on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.